ArticleJHLT open2026
Third time's the charm? Outcomes after third-time lung transplantation.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: With the increased success of redo lung transplantation (LTx), third-time LTx (3LTx) has emerged as a potential option for select patients with recurrent graft failure. We investigated outcomes after 3LTx compared to those of first-time (1LTx) and second-time (2LTx) lung transplantation. Methods: The United Network for Organ Sharing Standard Transplant Analysis and Research file was retrospectively analyzed for patients listed for 1LTx, 2LTx, and 3LTx between May 4, 2005, and March 28, 2025. Patient demographics, pretransplant characteristics, and postoperative outcomes were compared across groups. Results: A total of 40,419 patients were identified: 39,223 (97.0%) underwent 1LTx, 1161 (2.87%) underwent 2LTx, and 35 (0.09%) underwent 3LTx. Compared to the 2LTx cohort, 3LTx patients were younger (35 vs 46 years, p<0.001) and more likely to have been initially transplanted for cystic fibrosis (57% vs 35%, p=0.007). Postoperative complication rates were comparable; however, acute dialysis rates were higher in the 3LTx cohort (43% vs 18%, p<0.001). Median survival was comparable between the groups (2LTx: 3.58 years vs 3LTx: 2.90 years, p=0.295). In a multivariable analysis using 1LTx as the reference group, 3LTx was associated with an increased risk of death (aHR: 2.24, 95% CI: 1.12-4.49, p=0.023). Compared to 2LTx, 3LTx showed a nonsignificant trend toward higher mortality (aHR: 1.29, 95% CI: 0.64-2.60, p=0.48). Conclusions: Outcomes following 3LTx were largely comparable to those of 2LTx, despite increased renal complications. These findings suggest that 3LTx is a possible therapeutic option for carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.